Lung Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Lung Cancer, including details on symptoms, smoking, genetics, treatment, causes.

Volume 2 (2005), Issue 7 (July)

1. Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer.
   Int J Clin Oncol, 10(3): 157-64. [Abstract] [Full-text]
2. Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors.
   Int J Radiat Oncol Biol Phys, 62(4): 1003-8. [Abstract] [Full-text]
3. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
   Int J Radiat Oncol Biol Phys, 62(4): 995-1002. [Abstract] [Full-text]
4. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: a prospective clinical study.
   Int J Radiat Oncol Biol Phys, 62(4): 988-94. [Abstract] [Full-text]
5. Radiotherapy of human xenograft NSCLC tumors in nude mice with a 90Y-labeled anti-tissue factor antibody.
   Cancer Biother Radiopharm, 20(3): 300-9. [Abstract] [Full-text]
6. Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth.
   FEBS Lett, 579(17): 3829-36. [Abstract] [Full-text]
7. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.
   Cancer Res, 65(13): 5945-52. [Abstract] [Full-text]
8. A novel human tRNA-dihydrouridine synthase involved in pulmonary carcinogenesis.
   Cancer Res, 65(13): 5638-46. [Abstract] [Full-text]
9. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.
   Cancer Res, 65(13): 5561-70. [Abstract] [Full-text]
10. Bcl-2 promotes invasion and lung metastasis by inducing matrix metalloproteinase-2.
    Cancer Res, 65(13): 5554-60. [Abstract] [Full-text]
11. Differential expression of VASP in normal lung tissue and lung adenocarcinomas.
    Thorax, 60(7): 576-81. [Abstract] [Full-text]
12. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis.
    Thorax, 60(7): 570-5. [Abstract] [Full-text]
13. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer.
    Thorax, 60(7): 564-9. [Abstract] [Full-text]
14. Depletion of RLIP76 sensitizes lung cancer cells to doxorubicin.
    Biochem Pharmacol, 70(3): 481-8. [Abstract] [Full-text]
15. Rare SP-A alleles and the SP-A1-6A(4) allele associate with risk for lung carcinoma.
    Clin Genet, 68(2): 128-36. [Abstract] [Full-text]
16. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 130(1): 166-72. [Abstract] [Full-text]
17. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 130(1): 160-5. [Abstract] [Full-text]
18. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
    J Thorac Cardiovasc Surg, 130(1): 151-9. [Abstract] [Full-text]
19. Surgical treatment of solitary adrenal metastasis from non-small cell lung cancer.
    J Thorac Cardiovasc Surg, 130(1): 136-40. [Abstract] [Full-text]
20. Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
    J Thorac Cardiovasc Surg, 130(1): 125-30. [Abstract] [Full-text]
21. High-resolution genomic profiles of human lung cancer.
    Proc Natl Acad Sci U S A, 102(27): 9625-30. [Abstract] [Full-text]
22. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients.
    Br J Cancer, 93(1): 137-43. [Abstract] [Full-text]
23. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
    Br J Cancer, 93(1): 29-34. [Abstract] [Full-text]
24. Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients.
    Br J Cancer, 93(1): 23-8. [Abstract] [Full-text]
25. Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5057s-5062s. [Abstract] [Full-text]
26. Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5051s-5056s. [Abstract] [Full-text]
27. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5045s-5050s. [Abstract] [Full-text]
28. Surgical management of T3 and T4 lung cancer.
    Clin Cancer Res, 11(13): 5038s-5044s. [Abstract] [Full-text]
29. The role of surgery in N2 non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5033s-5037s. [Abstract] [Full-text]
30. Study design issues and early stage non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5030s-5032s. [Abstract] [Full-text]
31. The role of targeted agents in adjuvant therapy for non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5027s-5029s. [Abstract] [Full-text]
32. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
    Clin Cancer Res, 11(13): 5022s-5026s. [Abstract] [Full-text]
33. Adjuvant chemotherapy for non-small cell lung cancer: contribution of the International Adjuvant Lung Trial.
    Clin Cancer Res, 11(13): 5017s-5021s. [Abstract] [Full-text]
34. The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer.
    Clin Cancer Res, 11(13): 5011s-5016s. [Abstract] [Full-text]
35. Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy.
    Clin Cancer Res, 11(13): 5004s-5010s. [Abstract] [Full-text]
36. Future of early detection of lung cancer: the role of mouse models.
    Clin Cancer Res, 11(13): 4999s-5003s. [Abstract] [Full-text]
37. Clinical issues in the management of early lung cancer.
    Clin Cancer Res, 11(13): 4993s-4998s. [Abstract] [Full-text]
38. Limitations of screening for lung cancer with low-dose spiral computed tomography.
    Clin Cancer Res, 11(13): 4988s-4992s. [Abstract] [Full-text]
39. Computed tomography screening for lung cancer: principles and results.
    Clin Cancer Res, 11(13): 4984s-4987s. [Abstract] [Full-text]
40. Role of HIF signaling on tumorigenesis in response to chronic low-dose arsenic administration.
    Toxicol Sci, 86(2): 248-57. [Abstract] [Full-text]
41. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.
    Chest, 128(1): 452-62. [Abstract] [Full-text]
42. Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk.
    Chest, 128(1): 445-52. [Abstract] [Full-text]
43. Paracardiac opacity following inferior- and middle-lobe resection for bronchogenic carcinoma: unsuspected diagnosis.
    Chest, 128(1): 439-41. [Abstract] [Full-text]
44. A prospective study of the timing and cost-effectiveness of bronchial washing during bronchoscopy for pulmonary malignant tumors.
    Chest, 128(1): 394-400. [Abstract] [Full-text]
45. Electromagnetic catheter navigation during bronchoscopy: validation of a novel method by conventional fluoroscopy.
    Chest, 128(1): 382-7. [Abstract] [Full-text]
46. Lung cancer in women: emerging differences in epidemiology, biology, and therapy.
    Chest, 128(1): 370-81. [Abstract] [Full-text]
47. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.
    Chest, 128(1): 317-21. [Abstract] [Full-text]
48. Small tumor size and limited smoking history predicts activated epidermal growth factor receptor in early-stage non-small cell lung cancer.
    Chest, 128(1): 308-16. [Abstract] [Full-text]
49. Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database.
    Chest, 128(1): 237-45. [Abstract] [Full-text]
50. Chemotherapy for non-small cell lung cancer in elderly patients.
    Chest, 128(1): 132-9. [Abstract] [Full-text]
51. Lung cancer pathogenesis associated with wood smoke exposure.
    Chest, 128(1): 124-31. [Abstract] [Full-text]
52. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.
    Clin Chem Lab Med, 43(6): 617-27. [Abstract] [Full-text]
53. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes.
    J Neuroimmunol, 165(1): 166-71. [Abstract] [Full-text]
54. Progression analysis of lung squamous cell carcinomas by comparative genomic hybridization.
    Tumour Biol, 26(3): 158-64. [Abstract] [Full-text]
55. Increased expression of myosin light chain kinase mRNA is related to metastasis in non-small cell lung cancer.
    Tumour Biol, 26(3): 153-7. [Abstract] [Full-text]
56. Somatic genetic changes accompanying lung tumor development.
    Genes Chromosomes Cancer, 44(1): 65-75. [Abstract] [Full-text]
57. CYP1A1 and GSTM1 genetic polymorphisms in lung cancer populations exposed to arsenic in drinking water.
    Xenobiotica, 35(5): 519-30. [Abstract] [Full-text]
58. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    N Engl J Med, 353(2): 133-44. [Abstract] [Full-text]
59. Erlotinib in previously treated non-small-cell lung cancer.
    N Engl J Med, 353(2): 123-32. [Abstract] [Full-text]
60. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study.
    Int J Gynecol Cancer, 15(4): 646-56. [Abstract] [Full-text]
61. Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression.
    Oncogene, 24(30): 4806-12. [Abstract] [Full-text]
62. Lung tumor location and lymphocyte infiltration in mice are genetically determined.
    Exp Lung Res, 31(5): 513-25. [Abstract] [Full-text]
63. Microwave tumour coagulation plus in situ treatment with cytokine-microparticles: induction of potent anti-residual tumour immunity.
    Int J Hyperthermia, 21(3): 247-57. [Abstract] [Full-text]
64. Extensive metastasis to the hand from undiagnosed adenocarcinoma of the lung.
    Scand J Plast Reconstr Surg Hand Surg, 39(2): 113-5. [Abstract] [Full-text]
65. Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.
    Cancer Res, 65(14): 6476-83. [Abstract] [Full-text]
66. Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy.
    Cancer Res, 65(14): 6450-8. [Abstract] [Full-text]
67. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
    Cancer Res, 65(14): 6425-34. [Abstract] [Full-text]
68. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Cancer Res, 65(14): 6401-8. [Abstract] [Full-text]
69. Proteolytic processing converts the repelling signal Sema3E into an inducer of invasive growth and lung metastasis.
    Cancer Res, 65(14): 6167-77. [Abstract] [Full-text]
70. A mouse model for cyclin E-dependent genetic instability and tumorigenesis.
    Cancer Cell, 8(1): 35-47. [Abstract] [Full-text]
71. COX-2 inhibitors suppress integrin alpha5 expression in human lung carcinoma cells through activation of Erk: involvement of Sp1 and AP-1 sites.
    Int J Cancer, 116(4): 536-46. [Abstract] [Full-text]
72. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
    Eur J Cancer, 41(11): 1547-50. [Abstract] [Full-text]
73. Toxicity induced by the chemical carcinogen 7,12-dimethylbenz[a]anthracene and the protective effects of selenium in Wistar rats.
    J Toxicol Environ Health A, 68(9): 693-701. [Abstract] [Full-text]
74. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer.
    Eur J Cancer, 41(11): 1533-41. [Abstract] [Full-text]
75. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
    J Natl Cancer Inst, 97(14): 1080-3. [Abstract] [Full-text]
76. A molecular epidemiology case control study on pleural malignant mesothelioma.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1741-6. [Abstract] [Full-text]
77. Familial lung cancer and aggregation of smoking habits: a simulation of the effect of shared environmental factors on the familial risk of cancer.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1738-40. [Abstract] [Full-text]
78. An association between preoperative anemia and decreased survival in early-stage non-small-cell lung cancer patients treated with surgery alone.
    Int J Radiat Oncol Biol Phys, 62(5): 1438-43. [Abstract] [Full-text]
79. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer.
    Int J Radiat Oncol Biol Phys, 62(5): 1432-7. [Abstract] [Full-text]
80. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
    Br J Cancer, 93(2): 173-7. [Abstract] [Full-text]
81. Alternative splicing of MDM2 mRNA in lung carcinomas and lung cell lines.
    Environ Mol Mutagen, 46(1): 1-11. [Abstract] [Full-text]
82. Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase pathways.
    Carcinogenesis, 26(8): 1436-45. [Abstract] [Full-text]
83. The race associated allele of Semaphorin 3B (SEMA3B) T415I and its role in lung cancer in African-Americans and Latino-Americans.
    Carcinogenesis, 26(8): 1446-9. [Abstract] [Full-text]
84. Lambert-Eaton myasthenic syndrome has a more progressive course in patients with lung cancer.
    Muscle Nerve, 32(2): 226-9. [Abstract] [Full-text]
85. Thoracotomy is associated with significantly more profound suppression in lymphocytes and natural killer cells than video-assisted thoracic surgery following major lung resections for cancer.
    J Invest Surg, 18(2): 81-8. [Abstract] [Full-text]
86. Curcumin inhibits interferon-alpha induced NF-kappaB and COX-2 in human A549 non-small cell lung cancer cells.
    Biochem Biophys Res Commun, 334(2): 313-8. [Abstract] [Full-text]
87. Functional impairment of telomerase in sublines derived from human lung adenocarcinoma exposed to mild oxidative stress.
    Biochem Biophys Res Commun, 334(2): 450-9. [Abstract] [Full-text]
88. The Human mineral dust-induced gene, mdig, is a cell growth regulating gene associated with lung cancer.
    Oncogene, 24(31): 4873-82. [Abstract] [Full-text]
89. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma.
    Cancer Lett, 226(2): 123-31. [Abstract] [Full-text]
90. The role of trivalent dimethylated arsenic in dimethylarsinic acid-promoted skin and lung tumorigenesis in mice: tumor-promoting action through the induction of oxidative stress.
    Toxicol Lett, 158(2): 87-94. [Abstract] [Full-text]
91. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
    Cancer, 104(3): 561-9. [Abstract] [Full-text]
92. Oxygen-enhanced MR imaging: correlation with postsurgical lung function in patients with lung cancer.
    Radiology, 236(2): 704-11. [Abstract] [Full-text]
93. Aberrant promoter methylation of p16(INK4a), RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer.
    Int J Cancer, 116(5): 720-5. [Abstract] [Full-text]
94. Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China.
    Int J Cancer, 116(5): 768-73. [Abstract] [Full-text]
95. Case report: Gluteal injection site granulomas: false positive finding on FDG-PET in patients with non-small cell lung cancer.
    Br J Radiol, 78(932): 758-61. [Abstract] [Full-text]
96. Combined small-cell carcinoma of the stomach: p53 and K-ras gene mutational analysis supports a monoclonal origin of three histological components.
    Int J Exp Pathol, 86(4): 213-8. [Abstract] [Full-text]
97. Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin.
    Cancer Chemother Pharmacol, 56(4): 337-43. [Abstract] [Full-text]
98. Genes that mediate breast cancer metastasis to lung.
    Nature, 436(7050): 518-24. [Abstract] [Full-text]
99. Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
    Semin Respir Crit Care Med, 26(3): 342-52. [Abstract] [Full-text]
100. Treatment of small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 333-41. [Abstract] [Full-text]
101. New biological agents in the treatment of advanced non-small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 323-32. [Abstract] [Full-text]
102. Factors predicting response to EGFR tyrosine kinase inhibitors.
     Semin Respir Crit Care Med, 26(3): 314-22. [Abstract] [Full-text]
103. Chemotherapy in advanced non-small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 304-13. [Abstract] [Full-text]
104. The role of adjuvant chemotherapy for non-small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 298-303. [Abstract] [Full-text]
105. Treatment of advanced non-small cell lung cancer in the elderly.
     Semin Respir Crit Care Med, 26(3): 289-97. [Abstract] [Full-text]
106. The role of radiation therapy in non-small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 278-88. [Abstract] [Full-text]
107. Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation.
     Semin Respir Crit Care Med, 26(3): 273-7. [Abstract] [Full-text]
108. Molecular epidemiology of non-small cell lung cancer.
     Semin Respir Crit Care Med, 26(3): 265-72. [Abstract] [Full-text]
109. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
     J Clin Oncol, 23(22): 5007-18. [Abstract] [Full-text]
110. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer.
     J Clin Oncol, 23(22): 4999-5006. [Abstract] [Full-text]
111. Study of paclitaxel, etoposide, and cisplatin chemotherapy combined with twice-daily thoracic radiotherapy for patients with limited-stage small-cell lung cancer: a Radiation Therapy Oncology Group 9609 phase II study.
     J Clin Oncol, 23(22): 4991-8. [Abstract] [Full-text]

© 2004-2008 Lung Cancer Research Today. All Rights Reserved.